Matthew R. Cooperberg, MD, MPH
Matthew R. Cooperberg, MD, MPH
Matthew Cooperberg, MD, MPH received his undergraduate training from Dartmouth College, where he earned a degree in English with high honors. He then enrolled in Yale University's MD, MPH program, concurrently earning an MPH with a concentration in Health Policy from the School of Epidemiology and Public Health, and a MD from the School of Medicine. He completed his General Surgery and Urology training at the University of California, San Francisco, and subsequently continued at UCSF to complete a fellowship in Urologic Oncology under the guidance of Peter Carroll, MD, MPH. In 2009, Dr. Cooperberg was recruited to join the faculty at UCSF and the San Francisco Veterans Affairs Medical Center. Specializing in urologic cancer care, he is part of the multidisciplinary urologic oncology team of the UCSF Helen Diller Family Comprehensive Cancer Center, located primarily at the Mission Bay campus. He also maintains privileges at San Francisco General Hospital. In 2013, Cooperberg received the first Helen Diller Family Chair in Urology and a secondary appointment in the Department of Epidemiology and Biostatistics. In 2015 he won the American Urological Association Gold Cystoscope Award, given annually to one urologist for contributions to the field in the first 10 years of practice.
Dr. Cooperberg's clinical interests include the early detection, diagnosis, and management of genitourinary malignancy, and using minimally invasive techniques to treat benign and malignant diseases. He performs robotic, laparoscopic, endoscopic, and percutaneous surgeries, and is interested in incorporating promising new technologies into his practice. He is particularly interested in risk-stratifying prostate, renal, and other tumors, and matching treatments appropriately to those patients most likely to benefit, using novel imaging tests and biomarkers together with clinical information. Dr. Cooperberg is a Fellow of the American College of Surgeons, and a member of the American Urological Association (AUA) and the Society for Urologic Oncology. In 2012 Dr. Cooperberg co-wrote a proposal to establish a national urology registry. From this proposal developed the AUA Quality (AQUA) Registry, a national database tracking practice patterns, quality of care, and both clinical and patient-reported outcomes for patients across the U.S. with prostate cancer and other urologic conditions.
Drawing on the CaPSURE registry, UCSF’s institutional databases, and other data resources, Dr. Cooperberg has written over 190 peer-reviewed scientific articles, and has been invited to present his research findings at many national and international conferences. His primary research focus is prostate cancer, with particular areas of interest including: 1) health services research, documenting ongoing trends and regional variation in the use of diagnostic, imaging, and therapeutic interventions for men with all stages of prostate cancer; 2) risk assessment, developing and validating prognostic tools incorporating both standard clinical information and emerging biomarkers; 3) comparative effectiveness research, examining evidence regarding the relative benefits of surgery, radiation, and other treatments in terms of cancer control, quality of life, and cost; and 4) decision support and survivorship, helping men make better-informed decisions about both treatments and management of short- and long-term treatment sequelae. He is also very interested in prostate cancer as an international disease, and has helped forge a number of inter-continental collaborations which are yielding fascinating insights into prostate cancer’s variation in presentation and outcome around the world. He has received numerous awards for his research papers and is co-investigator on multiple grants. He won a prestigious Young Investigator Award from the Prostate Cancer Foundation, and is an investigator on a number of ongoing Federal grants.
1825 4th Street
4th floor UCSF Ron Conway Family Gateway Medical Building
San Francisco, CA 94158
Nurse Navigator for general questions
regarding making an appointment
New Patient Coordinator
University of California, San Francisco
Department of Urology, Mailcode 1695
550 16th Street, 6th Floor
San Francisco, CA 94143
matthewherper Billionaire Soon-Shiong touted as dark horse. t.co/qtytkqB0CG
dr_coops @uretericbud @MA_Preston @qdtrinh definitely after cystectomy. RP is still variable...Depends a bit on extent of LND, age, etc. Also copays.
dr_coops @daviesbj @ChapinMD yeah right... The chancellor gets $100M war chest and we get squat even though this was PRC's donor!
dr_coops Well, this is good news! Association of Leisure Time Physical Activity With Risk for Mortality | JAMA Internal t.co/9dw2lHj7xm
DrCzarniecki MR biopsy misses #prostatecancer in the dorsolateral prostate (58%) and TRUS biopsy in the anterior (79%) KEY paper… t.co/JaChHJAXMD
WallisCJD .@dr_coops @BJUIjournal agree. I just rejected a paper for the same. In Phoenix defn, only should be used 2yr less than median f/u! Thus 1yr
dr_coops I would love to see @EUplatinum @JUrology @BJUIjournal @pcan_journal all agree not to publish ablation articles using Phoenix outcomes #pcsm
dr_coops @WallisCJD Plus, median 3 yr followup and they're reporting 5-year outcomes— with Phoenix def!! @BJUIjournal should have called them out...
dr_coops The New Science of Exercise t.co/tNDgqJ61dS Nothing all that new but still a great summary article. @time
dr_coops HIFU after RT failure?? Poor outcomes (even with totally inappropriate use of Phoenix def), lots of complications. t.co/QmZq2PaD5j